There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Arvinas Holding Company (ARVN – Research ...

Charles Schwab Investment Management Inc. lifted its stake in shares of Arvinas, Inc. (NASDAQ:ARVN – Free Report) by 1.0% during the 4th quarter, according to its most recent disclosure with the ...

2025年3月19日， Arvinas（ARVN）披露1笔公司内部人交易情况。高管Berkowitz Noah于2025年3月18日卖出8658股。 2025年3月19日 高管 Berkowitz Noah 2025年3月18日 卖出 8658 8.59 7.44万 2025年2月25日 高管 Taylor Ian 2025年2月24日 卖出 1664 16.55 2.75万 2025年2月25日 ...

The phase 3 VERITAC-2 trial has been evaluating the candidate against AstraZeneca’s endocrine therapy Faslodex (fulvestrant) ...

We recently compiled a list of the 10 Pump and Dump Stocks Favored by Hedge Funds. In this article, we are going to take a ...

The heavy selling pressure might have exhausted for Arvinas (ARVN) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in ...

Arvinas’ cash burn and lack of pipeline candidates hurt its outlook. See why ARVN stock is a sell, despite a healthy cash ...

Arvinas (NASDAQ:ARVN – Get Free Report) was downgraded by analysts at Wedbush from an “outperform” rating to a “neutral” ...

Arvinas (ARVN) saw its shares surge in the last session with trading volume being higher than average. The latest trend in ...

Arvinas的三期数据之争，本质是新兴技术从概念到产品的必经试炼。尽管挫折当前，但ESR1突变亚组的成功，标志着PROTAC首次在实体瘤中证实临床价值。对行业而言，这一事件亦传递出明确信号：在“靶点内卷”的创新药红海中，技术突破需与精准医疗深度结合——谁能锁定优势亚群并优化临床设计，谁方能笑到最后。

Susquehanna cut Teradyne, Inc. TER price target from $165 to $155. Susquehanna analyst Mehdi Hosseini maintained a Positive ...

Arvinas (ARVN) stock faces a downgrade after underwhelming trial data for breast cancer drug vepdegestrant developed with ...